799 related articles for article (PubMed ID: 32305522)
21. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.
Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A
Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436
[TBL] [Abstract][Full Text] [Related]
22. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices.
MMWR Recomm Rep; 1996 Apr; 45(RR-4):1-18. PubMed ID: 8602127
[TBL] [Abstract][Full Text] [Related]
23. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.
Chen YY; Lin CW; Huang WF; Chang JR; Su IJ; Hsu CH; Cheng HY; Hsu SC; Dou HY
J Microbiol Immunol Infect; 2017 Feb; 50(1):90-96. PubMed ID: 25732698
[TBL] [Abstract][Full Text] [Related]
24. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
[TBL] [Abstract][Full Text] [Related]
25. What's Old and New in Tuberculosis Vaccines for Children.
Cranmer LM; Cotton MF; Day CL; Nemes E
J Pediatric Infect Dis Soc; 2022 Oct; 11(Supplement_3):S110-S116. PubMed ID: 36314550
[TBL] [Abstract][Full Text] [Related]
26. Development of tuberculosis vaccines in clinical trials: Current status.
Méndez-Samperio P
Scand J Immunol; 2018 Oct; 88(4):e12710. PubMed ID: 30175850
[TBL] [Abstract][Full Text] [Related]
27. Clinical Testing of Tuberculosis Vaccine Candidates.
Hatherill M; Tait D; McShane H
Microbiol Spectr; 2016 Oct; 4(5):. PubMed ID: 28087924
[TBL] [Abstract][Full Text] [Related]
28. Vaccination strategies to prevent tuberculosis in the new millennium: from BCG to new vaccine candidates.
Franco-Paredes C; Rouphael N; del Rio C; Santos-Preciado JI
Int J Infect Dis; 2006 Mar; 10(2):93-102. PubMed ID: 16377228
[TBL] [Abstract][Full Text] [Related]
29. Heterologous Boost Following
Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
Front Immunol; 2018; 9():2439. PubMed ID: 30425711
[TBL] [Abstract][Full Text] [Related]
30. Tuberculosis Vaccine Development: Progress in Clinical Evaluation.
Sable SB; Posey JE; Scriba TJ
Clin Microbiol Rev; 2019 Dec; 33(1):. PubMed ID: 31666281
[TBL] [Abstract][Full Text] [Related]
31. How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects.
Vilaplana C; Cardona PJ
Arch Bronconeumol (Engl Ed); 2019 Jul; 55(7):373-377. PubMed ID: 30594319
[TBL] [Abstract][Full Text] [Related]
32. Protection against tuberculosis by Bacillus Calmette-Guérin (BCG) vaccination: A historical perspective.
Setiabudiawan TP; Reurink RK; Hill PC; Netea MG; van Crevel R; Koeken VACM
Med; 2022 Jan; 3(1):6-24. PubMed ID: 35590145
[TBL] [Abstract][Full Text] [Related]
33. Next-Generation Vaccines Based on Bacille Calmette-Guérin.
Nieuwenhuizen NE; Kaufmann SHE
Front Immunol; 2018; 9():121. PubMed ID: 29459859
[TBL] [Abstract][Full Text] [Related]
34. Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014.
Whole Mycobacteria Cell Vaccines for Tuberculosis Summary Group
Vaccine; 2015 Jun; 33(26):3047-55. PubMed ID: 25882170
[TBL] [Abstract][Full Text] [Related]
35. Current perspective in tuberculosis vaccine development for high TB endemic regions.
Husain AA; Daginawala HF; Singh L; Kashyap RS
Tuberculosis (Edinb); 2016 May; 98():149-58. PubMed ID: 27156631
[TBL] [Abstract][Full Text] [Related]
36. Novel vaccine candidates against Mycobacterium tuberculosis.
Khoshnood S; Heidary M; Haeili M; Drancourt M; Darban-Sarokhalil D; Nasiri MJ; Lohrasbi V
Int J Biol Macromol; 2018 Dec; 120(Pt A):180-188. PubMed ID: 30098365
[TBL] [Abstract][Full Text] [Related]
37. BCG-mediated protection against M. tuberculosis is sustained post-malaria infection independent of parasite virulence.
Tangie E; Walters A; Hsu NJ; Fisher M; Magez S; Jacobs M; Keeton R
Immunology; 2022 Feb; 165(2):219-233. PubMed ID: 34775598
[TBL] [Abstract][Full Text] [Related]
38. Current challenges and opportunities for bacillus Calmette-Guérin replacement vaccine candidates.
Méndez-Samperio P
Scand J Immunol; 2019 Oct; 90(4):e12772. PubMed ID: 31055842
[TBL] [Abstract][Full Text] [Related]
39. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
Nemes E; Geldenhuys H; Rozot V; Rutkowski KT; Ratangee F; Bilek N; Mabwe S; Makhethe L; Erasmus M; Toefy A; Mulenga H; Hanekom WA; Self SG; Bekker LG; Ryall R; Gurunathan S; DiazGranados CA; Andersen P; Kromann I; Evans T; Ellis RD; Landry B; Hokey DA; Hopkins R; Ginsberg AM; Scriba TJ; Hatherill M;
N Engl J Med; 2018 Jul; 379(2):138-149. PubMed ID: 29996082
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
